- Home
- CYCN vs RNAZ Comparison
CYCN vs RNAZ Comparison
Compare CYCN & RNAZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CYCN | RNAZ |
|---|---|---|
| Founded | 2018 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.7M | 5.6M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | CYCN | RNAZ |
|---|---|---|
| Price | $3.69 | $8.73 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 23.4K | ★ 24.6K |
| Earning Date | 05-08-2026 | 04-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.03 | $3.82 |
| 52 Week High | $8.48 | $20.99 |
Technical Indicators
Market Signals| Indicator | CYCN | RNAZ |
|---|---|---|
| Relative Strength Index (RSI) | 62.77 | 64.77 |
| Support Level | $2.93 | $8.38 |
| Resistance Level | $8.48 | $9.68 |
| Average True Range (ATR) | 0.22 | 1.17 |
| MACD | 0.04 | 0.45 |
| Stochastic Oscillator | 66.65 | 74.02 |
Price Performance
Historical ComparisonAbout CYCN Cyclerion Therapeutics Inc.
Cyclerion Therapeutics Inc is a clinical-stage biopharmaceutical company harnessing the power of soluble guanylate cyclase (sGC) pharmacology to discover, develop, and commercialize breakthrough treatments for serious and orphan diseases. Its focus is on enabling the full therapeutic potential of next-generation sGC stimulators. Its pipeline products include Olinciguat, Praliciguat, and others.
About RNAZ TransCode Therapeutics Inc.
TransCode Therapeutics Inc is a clinical-stage biotechnology company engaged in the development of RNA-based therapeutics and immuno-oncology treatments for cancer. The company's lead candidate, TTX-MC138, targets microRNA-10b and has completed a Phase 1a clinical trial, while it is also advancing additional product candidates, including a cancer vaccine and an oncolytic immunotherapy platform.